AKT1 and type 2 diabetes mellitus: The insulin PI3K/Akt pathway has been widely targeted in T2DM pharmacotherapy (World Health Organization, 2019; Naowaboot et al., 2012; Luna-Vital & De Mejia, 2018) and is important in the pathophysiology and therapy of other diseases (Nurcahyanti et al., 2021).